A novel microrna signature with clinical significance in multiple myeloma

by A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, A. Scorilas, E. Terpos
Published 2020-10-01

Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells

by K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, O. Tsitsilonis, E. Terpos
Published 2020-10-01

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

by E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, N. Kanellias, M. Migkou, M. Roussou, M. Gavriatopoulou, E. Hatjiharissi, M. Cavo, M. Dimopoulos
Published 2020-10-01

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

by J. Caers, B. Paiva, E. Zamagni, X. Leleu, J. Bladé, S. Y. Kristinsson, C. Touzeau, N. Abildgaard, E. Terpos, R. Heusschen, E. Ocio, M. Delforge, O. Sezer, M. Beksac, H. Ludwig, G. Merlini, P. Moreau, S. Zweegman, M. Engelhardt, L. Rosiñol
Published 2018-01-01